Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

100.47
+2.242.28%
Volume:588.73K
Turnover:58.85M
Market Cap:6.02B
PE:-119.71
High:101.08
Open:100.02
Low:97.49
Close:98.23
52wk High:105.74
52wk Low:36.88
Shares:59.88M
Float Shares:39.99M
Volume Ratio:0.73
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8393
EPS(LYR):-1.8505
ROE:-15.81%
ROA:-3.60%
PB:20.60
PE(LYR):-54.29

Loading ...

Company Profile

Company Name:
Mirum Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
355
Office Location:
950 Tower Lane,Suite 1050,Foster City,California,United States
Zip Code:
94404
Fax:
- -
Introduction:
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Directors

Name
Position
Christopher Peetz
President and Chief Executive Officer and Director
Michael Grey
Chairman of the Board
Laura Brege
Director
Laurent Fischer
Director
Lon Cardon
Director
Niall O'Donnell
Director
Patrick Heron
Director
Saira Ramasastry
Director
Timothy Walbert
Director
William Fairey
Director

Shareholders

Name
Position
Christopher Peetz
President and Chief Executive Officer and Director
Peter Radovich
Chief Operating Officer
Lara Longpre
Chief Development Officer
Pamela Vig
Head of Research and Development